Literature DB >> 24698569

What is the most reliable solid culture medium for tuberculosis treatment trials?

Moses L Joloba1, John L Johnson2, Pei-Jean I Feng3, Lorna Bozeman4, Stefan V Goldberg5, Karen Morgan6, Phineas Gitta7, Henry W Boom8, Charles M Heilig9, Harriet Mayanja-Kizza10, Kathleen D Eisenach11.   

Abstract

We conducted a prospective study to determine which solid medium is the most reliable overall and after two months of therapy to detect Mycobacterium tuberculosis complex (MTB). MTB isolation and contamination rates on LJ and Middlebrook 7H10 and 7H11 agar with and without selective antibiotics were examined in a single laboratory and compared against a constructed reference standard and MGIT 960 results. Of 50 smear positive adults with pulmonary TB enrolled, 45 successfully completed standard treatment. Two spot sputum specimens were collected before treatment and at week 8 and one spot specimen each at weeks 2, 4, 6, and 12. The MTB recovery rate among all solid media for pre-treatment specimens was similar. After 8 weeks, selective (S) 7H11 had the highest positivity rate. Latent class analysis was used to construct the primary reference standard. The 98.7% sensitivity of 7H11S (95% Wilson confidence interval 96.4%-99.6%) was highest among the 5 solid media (P = 0.003 by bootstrap); the 82.6% specificity of 7H10S (95% CI 75.7%-87.8%) was highest (P = 0.098). Our results support 7H11S as the medium of choice. Further studies in different areas where recovery and contamination are likely to vary, are recommended.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug trials; LCA; Mycobacterium tuberculosis; Solid media

Mesh:

Substances:

Year:  2014        PMID: 24698569     DOI: 10.1016/j.tube.2014.03.002

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  8 in total

1.  Medium matters: modeling the impact of solid medium performance on tuberculosis trial sample size requirements.

Authors:  M G Johnson; J E Stout; D A Benator; W C Whitworth; D P Holland
Journal:  Int J Tuberc Lung Dis       Date:  2016-05       Impact factor: 2.373

2.  Evaluation of Mycotube, a modified version of Lowenstein-Jensen (LJ) medium, for efficient recovery of Mycobacterium tuberculosis (MTB).

Authors:  R Nambiar; S Chatellier; N Bereksi; A van Belkum; N Singh; B Barua; A Shetty; C Rodrigues
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-06       Impact factor: 3.267

3.  Comparison of Mycobacterium tuberculosis complex Yield and Contamination Rates using Lowenstein-Jensen with and without Antibiotics in Western Kenya.

Authors:  A Okumu; K McCarthy; J Orwa; J Williamson; S Musau; H Alexander; S Cavanaugh; S Modi; K Cain
Journal:  J Med Sci Clin Res       Date:  2017

4.  A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing.

Authors:  Koné Kaniga; Daniela M Cirillo; Sven Hoffner; Nazir A Ismail; Devinder Kaur; Nacer Lounis; Beverly Metchock; Gaby E Pfyffer; Amour Venter
Journal:  J Clin Microbiol       Date:  2016-09-21       Impact factor: 5.948

5.  How we determined the most reliable solid medium for studying treatment of tuberculosis.

Authors:  Charles M Heilig; Pei-Jean I Feng; Moses L Joloba; John L Johnson; Karen Morgan; Phineas Gitta; W Henry Boom; Harriet Mayanja-Kizza; Kathleen D Eisenach; Lorna Bozeman; Stefan V Goldberg
Journal:  Tuberculosis (Edinb)       Date:  2014-03-04       Impact factor: 3.131

6.  Performance of QuantaMatrix Microfluidic Agarose Channel system integrated with mycobacteria growth indicator tube liquid culture.

Authors:  Hyejin Kim; Sangyeop Lee; EunJi Jo; Suyeoun Kim; Haeun Kim; Eun-Geun Kim; Sunghoon Kwon; Soyoun Shin
Journal:  Appl Microbiol Biotechnol       Date:  2021-07-30       Impact factor: 4.813

7.  Agreement of Middle brook 7H10 with Lowenstein Jensen and accuracy of the Sensititre MYCOTB plate using either method as a reference standard for Mycobacterium tuberculosis first line drug susceptibility testing.

Authors:  Willy Ssengooba; Germine Nakayita; Carolyn C Namaganda; Moses L Joloba
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

8.  Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts.

Authors:  Aksana Jones; Jay Saini; Belinda Kriel; Laura E Via; Yin Cai; Devon Allies; Debra Hanna; David Hermann; Andre G Loxton; Gerhard Walzl; Andreas H Diacon; Klaus Romero; Ryo Higashiyama; Yongge Liu; Alexander Berg
Journal:  BMC Infect Dis       Date:  2022-04-02       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.